ABSTRACT
B-cell acute lymphoblastic leukemia/lymphoma (B-ALL/LBL) is a lymphoproliferative disorder of immature B-cells with blastic morphology and specific phenotype (CD10+/−, CD19+, CD20−, CD22+/−, cCD79a+, CD34+, TdT+, and CD45+/−) [1–6]. Several clinical, phenotypic, and genetic features define prognosis in B-ALL. The total WBC count at the time of diagnosis is the single most powerful clinical predictor of remission induction and duration, and long-term survival for all age-groups [7–9]. Patients with high white blood cell (WBC) counts often have extramedullary disease at diagnosis and are at high risk for relapse in central nervous system (CNS) and testes. Age at diagnosis, certain chromosomal changes, immunophenotype, and persistence of leukemia after induction therapy comprise other important prognostic parameters [10–12].
